The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neutrophil lymphocyte ratio (NLR) as a predictive biomarker for PD-1/PD-L1 directed therapy in metastatic non-small cell lung cancer (NSCLC).
 
Naresh Bumma
No Relationships to Disclose
 
Ghayathri Jeyakumar
No Relationships to Disclose
 
Seongho Kim
No Relationships to Disclose
 
Cathy Galasso
No Relationships to Disclose
 
Manish K. Thakur
No Relationships to Disclose
 
Shirish M. Gadgeel
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Genentech/Roche
Research Funding - ACEA Biosciences (Inst); Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Antoinette J. Wozniak
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech/Roche; Lilly; Novartis
Research Funding - Astex Pharmaceuticals; Boehringer Ingelheim